Try our beta test site
IMPORTANT: Listing of a study on this site does not reflect endorsement by the National Institutes of Health. Talk with a trusted healthcare professional before volunteering for a study. Read more...
56 studies found for:    brentuximab Vedotin | Open Studies
Show Display Options
Rank Status Study
1 Recruiting Brentuximab Vedotin in Patients With Relapsed or Refractory EBV-and CD30-positive Lymphomas
Condition: Relapsed or Refractory EBV-and CD30-positive Lymphomas
Intervention: Drug: brentuximab vedotin
2 Recruiting Trial of Adcetris in CD30+ Malignant Mesothelioma
Conditions: Lung Diseases Due to External Agents;   Mesothelioma
Intervention: Drug: Brentuximab Vedotin
3 Recruiting Brentuximab Vedotin for Relapsed/Refractory CD30-positive Non-Hodgkin Lymphomas
Condition: Non-Hodgkin Lymphoma
Intervention: Drug: Brentuximab vedotin
4 Recruiting Study of Rituximab and Brentuximab Vedotin for Relapsed Classical Hodgkin Lymphoma
Condition: Lymphoma
Intervention: Drug: Brentuximab vedotin & Rituximab
5 Recruiting Brentuximab Vedotin and Imatinib in Patients With Relapsed or Refractory ALK+ ALCL
Condition: ALK+ Anaplastic Large Cell Lymphoma
Interventions: Drug: Brentuximab vedotin;   Drug: Imatinib
6 Recruiting Brentuximab Vedotin in Treating Patients With Advanced Systemic Mastocytosis or Mast Cell Leukemia
Conditions: Aggressive Systemic Mastocytosis;   Mast Cell Leukemia;   Systemic Mastocytosis
Intervention: Drug: brentuximab vedotin
7 Recruiting Brentuximab Vedotin (Recombinant) for IV Infusion - Special Drug Use Surveillance (All-case Surveillance) "Relapsed or Refractory CD30+ Hodgkin's Lymphoma or Anaplastic Large Cell Lymphoma"
Condition: Relapsed or Refractory CD30+ Hodgkin's Lymphoma or Anaplastic Large Cell Lymphoma
Intervention: Drug: Brentuximab vedotin (recombinant)
8 Recruiting Brentuximab Vedotin in Chinese Participants With Relapsed/Refractory CD30-Positive Hodgkin Lymphoma (HL) or Systemic Anaplastic Large Cell Lymphoma (sALCL)
Conditions: Hodgkin Disease;   Lymphoma, Large-Cell, Anaplastic
Intervention: Drug: Brentuximab Vedotin
9 Recruiting A Phase II Study of Single Agent Brentuximab Vedotin in Relapsed/Refractory CD30 Low (<10%) Mature T Cell Lymphoma (TCL)
Conditions: T-cell Lymphoma;   Angioimmunoblastic T-cell Lymphoma;   Hepato-splenic T-cell Lymphoma;   Adult T-cell Leukemia/Lymphoma;   Enteropathy Associated T-cell Lymphoma;   NK T-cell Lymphoma;   Transformed Mycosis Fungoides
Intervention: Drug: Brentuximab vedotin
10 Recruiting Brentuximab Vedotin in High-Risk CD30+ Lymphoma Post Allogeneic Stem Cell Transplantation (AlloSCT)
Condition: Lymphoma
Intervention: Drug: Brentuximab Vedotin
11 Recruiting Study on the Role of Brentuximab Vedotin as Single Agent in the Treatment of Relapsed/Refractory CD30+ PTCL Patients
Condition: Lymphatic Diseases
Intervention: Drug: Brentuximab Vedotin
12 Recruiting Dose Ranging Study of Brentuximab Vedotin in Adults With Lupus
Condition: Systemic Lupus Erythematosus
Interventions: Drug: Brentuximab vedotin;   Drug: Placebo
13 Recruiting A Study of Brentuximab Vedotin Combined With Nivolumab for Relapsed or Refractory Hodgkin Lymphoma
Condition: Hodgkin Lymphoma
Interventions: Drug: brentuximab vedotin;   Drug: nivolumab
14 Recruiting A Phase II Study of Brentuximab Vedotin (BV) in the Treatment of Elderly Hodgkin Lymphoma (HL) Patients at First Relapse or With Primary Refractory Disease.
Condition: Hodgkin Lymphoma
Intervention: Drug: Brentuximab Vedotin
15 Not yet recruiting A Study of Brentuximab Vedotin + Adriamycin, Vinblastine, and Dacarbazine in Pediatric Participants With Advanced Stage Newly Diagnosed Hodgkin Lymphoma
Condition: Hodgkin Disease
Interventions: Drug: Brentuximab vedotin;   Drug: Doxorubicin;   Drug: Vinblastine;   Drug: Dacarbazine
16 Recruiting Study of Brentuximab Vedotin And Bevacizumab In Refractory CD-30 Positive Germ Cell Tumors
Condition: Germ Cell Tumor
Interventions: Drug: Brentuximab Vedotin;   Drug: Bevacizumab
17 Not yet recruiting Alsertib (MLN8237) and Brentuximab Vedotin for Relapsed/Refractory CD30-Positive Lymphomas and Solid Malignancies
Conditions: CD30-positive Lymphoma;   CD30-positive Solid Tumor
Interventions: Drug: Brentuximab Vedotin;   Drug: Alsertib
18 Recruiting Everolimus and Brentuximab Vedotin in Treating Patients With Relapsed or Refractory Hodgkin Lymphoma
Conditions: Recurrent Hodgkin Lymphoma;   Refractory Hodgkin Lymphoma
Interventions: Drug: Brentuximab Vedotin;   Drug: Everolimus;   Other: Laboratory Biomarker Analysis;   Other: Pharmacological Study
19 Recruiting Brentuximab Vedotin and Lenalidomide for Relapsed or Refractory Diffuse Large B-cell Lymphoma
Condition: Lymphoma, Large B-Cell, Diffuse
Interventions: Drug: Brentuximab vedotin;   Drug: Lenalidomide
20 Recruiting An Investigational Immuno-therapy Safety and Effectiveness Study of Nivolumab in Combination With Brentuximab Vedotin to Treat Non-Hodgkin Lymphomas
Condition: Non-Hodgkin's Disease
Interventions: Biological: Nivolumab;   Drug: Brentuximab Vedotin

   Previous Page Studies Shown (1-20) Next Page (21-40) Show next page of results    Last Page
Study has passed its completion date and status has not been verified in more than two years.